Latest Breaking News On - Head of global clinical development - Page 12 : comparemela.com

AstraZeneca (AZN) Announces Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-mutated HER2-negative High-risk Early Breast Cancer

AstraZeneca (AZN) Announces Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-mutated HER2-negative High-risk Early Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomDave fredricksonAndrew tuttRoy baynesKing college londonDrug administrationAmerican society of clinical oncology annual meetingResearch laboratoriesInstitute of cancer researchHead of global clinical developmentEuropean society for medical oncologyOlympia phaseClinical oncology annual meetingNew england journal

LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesCity ofUnited kingdomDave fredricksonAndrew tuttRoy baynesKing college londonMerck research laboratoriesAmerican society of clinical oncologyDrug administrationUs national cancer instituteFrontier science technology research foundationBreast international groupMerck co incInstitute of cancer researchHead of global clinical development

Lynparza approved in US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Lynparza approved in US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofDave fredricksonDaiichi sankyoAndrew tuttRoy baynesKing college londonDrug administrationUs national cancer instituteFrontier science technology research foundationBreast international groupCompany on twitter astrazenecaAmerican society of clinical oncology annual meetingMerck co incResearch laboratories

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza combo delays progression risk in prostate

Investegate announcements from AstraZeneca PLC, Lynparza combo delays progression risk in prostate

United statesUnited kingdomFred saadRoy baynesAdrian kempSusan galbraithAmerican society of clinical oncologyInternational journal of clinical practiceData monitoring committeeUniversity of montreal hospital centerMerck co incCompany on twitter astrazenecaResearch laboratoriesInvestor relations teamHead of global clinical developmentClinical oncology

AstraZeneca and MSD s Lynparza combo delays progression risk in prostate cancer

AstraZeneca and MSD's Lynparza combo delays progression risk in prostate cancer

United statesFred saadRoy baynesSusan galbraithResearch laboratoriesAmerican society of clinical oncologyHead of global clinical developmentData monitoring committeeUniversity of montreal hospital centerAmerican societyClinical oncologyGenitourinary cancersGenitourinary oncologyMontreal hospital centerSenior vice presidentGlobal clinical development